Not exact matches
The Institute's phenotyping platforms are adapted for the
study of mutant mice and genetic reference populations but can also be used for preclinical
studies including the
validation of therapeutic
targets as well as pharmacological and toxicological
studies in the mouse.
We are now extending the previous metabolomics genetics
studies to inform drug development in a project funded by the Center for Therapeutic
Target Validation.
The phenotyping platforms of PHENOMIN - ICS area, adapted to
study genetically modified mouse models, can also be used for preclinical
studies, including the
validation of therapeutic
targets, as well as pharmaceutical and toxicological
studies in mice.
The role of new genetic pathways in cancer biochemistry (the genome mutation profiles), the identification of the key
targets and their
validation, as well as utilization of new knock - out or knock - in animal models for such
studies are among topics that will be discussed.
The expertise displayed by the teams and the platforms of the Department of Translational Research allows the support for maturation of translational research projects (proof of concept in vivo,
target / biomarker identification and
validation, ancillary biological
studies coupled to clinical trials,...) of the Institut Curie alone or in collaboration with other academic teams or industrial partners.
These analyses represent a discovery phase of our
studies on CFS and nPTLS, generating
targets which can be followed up in future verification and
validation stages
studies [13].
This is in contrast to subsequent
validation studies where
targeted approaches are used and which do require knowledge of
target proteins.
Together these analyses represent the discovery phase of our
studies on CFS and nPTLS, generating
targets for follow up verification and
validation in the later stages of the biomarker discovery workflow [13].
These laboratories are complemented by several additional laboratories: one that is focused on computational structure prediction and design (Phil Bradley), one that conducts solution - based protein mapping
studies of large complexes involved in gene transcription (Steve Hahn) and a third that conducts drug
target validation and drug screening
studies (Julian Simon).
Validation studies and resulting documentation within the Ozone CCI will address the following
targets:
As a supplement to APT
Validation Study II, the research aims for
Validation Study III are to (1) generate master scores for video clips of youth program observations without cultural bias, (2) create more tailored and
targeted online training and anchor systems, and (3) eliminate significant differences in certification passing rates between groups with different cultural vantage points (i.e., Black vs. White raters, urban vs. non-urban program experiences).